Zymeworks (ZYME) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Oct, 2026Executive summary
Annual stockholder meeting scheduled virtually for Dec. 15, 2026, at 9:00 a.m. PT; six matters are submitted for a vote.
Voting matters and shareholder proposals
Board recommends FOR all director nominees and Proposals 2, 4, 5 and 6; it recommends a 1-year frequency for Proposal 3.
Proposals cover executive compensation, say-on-pay vote frequency, the 2026 Employee Stock Purchase Plan, board declassification and KPMG LLP’s auditor appointment for FY ending Dec. 31, 2026.
Board of directors and corporate governance
Director nominees are Brian N. Cherry, Gregory A. Ciongoli and Oleg Nodelman.
Proposal 5 seeks approval to amend and restate the certificate of incorporation to declassify the board.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Zymeworks
- Royalty cash flows fund a partnered R&D engine and selective value compounding.ZYME
Corporate presentation - Shareholders face six proposals, including a transition to annual director elections by 2029.ZYMEProxy filing
- Roche licenses ZW209 as ZW191 shows a 64.5% response rate.ZYMEInvestor update
- A six-proposal agenda pairs a new ESPP with a path to annual director elections by 2029.ZYMEProxy filing
- Theravance adds YUPELRI cash flows and R&D upside, funded by a non-recourse note.ZYMEM&A announcement
- FDA approval, robust pipeline, and strategic partnerships drive growth and shareholder value.ZYMEMorgan Stanley 24th Annual Global Healthcare Conference
- Scalable growth driven by partnerships, robust pipeline, and strong financial outlook.ZYMECorporate presentation
- FDA approval for zanidatamab and strategic acquisitions drive growth and innovation.ZYMEWells Fargo 21st Annual Healthcare Conference
- Revenue fell 91% year-over-year, with a net loss of $89.2M and major milestones pending.ZYMEQ2 2026